Tetanus primer significantly improves survival after immunotherapy for glioblastoma
the ONA take:
A study led by Duke Cancer Institute researchers demonstrated that an innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
Earlier research findings showed that glioblastoma tumors harbor a strain of cytomegalovirus (CMV) not present in the brain tissue around the tumor. This provides a natural target for immunotherapy.
Using dendritic cells, the researchers created a vaccine for the tumor. Patients with glioblastoma typically survive for little more than 1 year after diagnosis; however, after receiving the immunotherapy, half lived nearly 5 years or longer from their diagnosis.
Looking to expand on the effectiveness of the treatment, the researchers chose to use a shot of tetanus/diphtheria toxoid to incite the patient’s immune system.
In a blinded trial involving 12 patients with brain tumor, half were randomly selected to receive the tetanus shot; the other half received a placebo injection. The patients who received the tetanus shot had significantly longer survival than those who received the dendritic cell therapy alone (51-101 months vs 11.6 months).
One patient in the tetanus group continues to show no tumor growth and is still alive 8 years after the treatment.
An innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|